PharmaLundensis AB (XSAT:PHAL) ROE % Adjusted to Book Value: -52.21% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:PHAL PharmaLundensis AB XSAT:PHAL
25 GF Score
Price kr0.32
! 1 Warning Sign
View Full Analysis

What is PharmaLundensis AB ROE % Adjusted to Book Value?

PharmaLundensis AB XSAT:PHAL 25 ROE % Adjusted to Book Value is -52.21% as of Mar. 2026. GuruFocus rates XSAT:PHAL with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

PharmaLundensis AB's ROE % for the quarter that ended in Mar. 2026 was -205.70%. PharmaLundensis AB's PB Ratio for the quarter that ended in Mar. 2026 was 3.94. PharmaLundensis AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -52.21%.

PharmaLundensis AB ROE % Adjusted to Book Value Related Terms

PharmaLundensis AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for PharmaLundensis AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaLundensis AB ROE % Adjusted to Book Value Chart

PharmaLundensis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.30 -9.48 -29.39 -12.18 -41.05

PharmaLundensis AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.97 -34.31 -21.03 -38.86 -52.21

XSAT:PHAL vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, PharmaLundensis AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaLundensis AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's ROE % Adjusted to Book Value falls into.


XSAT:PHAL
25GF Score
PharmaLundensis AB XSAT:PHAL
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaLundensis AB ROE % Adjusted to Book Value Calculation

PharmaLundensis AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-210.58% / 5.13
=-41.05%

PharmaLundensis AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-205.70% / 3.94
=-52.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -52.21% mean?
PharmaLundensis AB (XSAT:PHAL) has a ROE % Adjusted to Book Value of -52.21% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PharmaLundensis AB and its competitors.
Is PharmaLundensis AB's ROE % Adjusted to Book Value too high?
PharmaLundensis AB's current ROE % Adjusted to Book Value is -52.21%. Overall, PharmaLundensis AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does PharmaLundensis AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
PharmaLundensis AB's ROE % Adjusted to Book Value of -52.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PharmaLundensis AB and its competitors. PharmaLundensis AB's current ROE % Adjusted to Book Value is -52.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaLundensis AB stock overvalued right now?
PharmaLundensis AB (XSAT:PHAL) has a current ROE % Adjusted to Book Value of -52.21%. The current ROE % Adjusted to Book Value is -52.21%. PharmaLundensis AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For PharmaLundensis AB (XSAT:PHAL), the current ROE % Adjusted to Book Value is -52.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaLundensis AB Business Description

Address PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
25GF Score

Get the complete analysis for XSAT:PHAL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price